Agonist or antagonist: what is preferable for in vitro fertilization?

References

• Halmos G, Schally AV. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix. Proc Natl Acad Sci USA 2002;99:961–965.
   PubMedGoogle Scholar
• Kovacs M, Schally AV, Csemus B, Rekasi Z. Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix down regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. Proc Natl Acad Sci USA 2001;98:1829–1834.
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874–885.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Aboulghar M, Mansour R, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed vs Flexible protocol. Rerod Bimed Online 2005;10:567–570.
   PubMed Web of Science ®Google Scholar
• Daya S. GnRH-agonists versus antagonist in assisted reproduction-a systemic review. Abstract book of the 8th international symposium on GnRH − Analogues in Cancer and Human Reproduction. 2005; A100.
   Google Scholar
• Kolibianakis EM, Albano C, Kahn J, Camus M, Tuornaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone releasing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles in associated with reduced chances of pregnancy. Fertil Steril 2003;79:873–880.
   PubMed Web of Science ®Google Scholar
• Escudero E, Bosch E, Crespo J, Simón C, Remohí J, Pellicer A. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril 2004;81:562–566.
   Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 2004;8:524–527.
   PubMedGoogle Scholar
• Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W, Cahill D. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004;19:90–95.
   PubMed Web of Science ®Google Scholar
• Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM, Diedrich K. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002;17:2842–2845.
   PubMed Web of Science ®Google Scholar
• Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048–2051.
   PubMed Web of Science ®Google Scholar
• Wikland M, Bergh C, Borg K, Hillensjö T, Howles CM, Knutsson A, Nilsson L, Wood M. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001;16:1676–1681.
   PubMed Web of Science ®Google Scholar
• Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J, Frydman R. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 1994;62:468–476.
   PubMed Web of Science ®Google Scholar
• Wilcox J, Potter D, Moore M, Ferrande L, Kelly E; CAP IV Investigator Group. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 2005;84:108–117.
   PubMed Web of Science ®Google Scholar
• Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003–1008.
   PubMed Web of Science ®Google Scholar
• Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Théron L, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004;19:1979–1984.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 2005;20:1200–1206.
   PubMed Web of Science ®Google Scholar
• Kolibianakis E, Zikopoulos K, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Hum Reprod 2004;19:2545–2549.
   PubMedGoogle Scholar
• Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005;83:1607–1611.
   PubMed Web of Science ®Google Scholar
• Balasch J, Tur R, Creus M, Buxaderas R, Fábregues F, Ballescá JL, Barri PN, Vanrell JA. Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol Endocrinol 1994;8:7–12.
   PubMed Web of Science ®Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004;81:1–5.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R. Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006;13:198–201.
   Google Scholar
• Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12:159–168.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod 2005;20:2373–2375.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF: a randomized controlled trial. Hum Reprod 2006;21:352–357.
   PubMed Web of Science ®Google Scholar
• Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 2005;83:321–330.
   PubMed Web of Science ®Google Scholar
• Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000;15:1211–1216.
   PubMed Web of Science ®Google Scholar
• Lee JR, Choi YS, Jee BC, Ku SY, Suh CS, Kim KC, Lee WD, Kim SH. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles. Fertil Steril 2007;88:1344–1349.
   Google Scholar
• Rabinerson J, Meltcer S, Zohav E, Gemer O, Anteby E, Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome. Fertil Steril 2008;89:472–474.
   Google Scholar
• Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vanderzwalmen P, Schoysman R, Makedos G. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 2005;20:1516–1520.
   PubMed Web of Science ®Google Scholar
• Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526–531.
   PubMed Web of Science ®Google Scholar
• Mohamed KA, Davies WA, Allsopp J, Lashen H. Agonist “flare-up” versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil Steril 2005;83:331–335.
   PubMed Web of Science ®Google Scholar
• Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001;16:868–870.
   PubMed Web of Science ®Google Scholar
• Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, Haines CJ. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005;20:616–621.
   PubMed Web of Science ®Google Scholar
• Schmidt DW, Bremner T, Orris JJ, Maier DB, Benadiva CA, Nulsen JC. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril 2005;83:1568–1571.
   PubMed Web of Science ®Google Scholar
• Ng EH, Tang OS, Ho PC. The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme. Hum Reprod 2000;15:1937–1942.
   PubMed Web of Science ®Google Scholar
• Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69:505–510.
   PubMed Web of Science ®Google Scholar
• Jurema MW, Bracero NJ, Garcia JE. Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. Fertil Steril 2003;80:1156–1161.
   Google Scholar
• Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006;CD004635.
   Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651–671.
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003;9:61–76.
   PubMed Web of Science ®Google Scholar